New generation NSAIDs: The benefits without the risks?

Drugs of Today

Volumn 33, Issue 6, 1997, Pages 371-378

  Wallace, John L ^a   Chin, Beth C ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b AltaPharm International Ltd   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 4 NITROXYBUTYL ESTER; ETODOLAC; FLURBIPROFEN; MELOXICAM; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

DRUG DEVELOPMENT; DRUG MECHANISM; DRUG SAFETY; ENANTIOMER; GASTROINTESTINAL SYMPTOM; HUMAN; NEPHROTOXICITY; REVIEW; STEREOSPECIFICITY;

EID: 0030818222     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Garner, A. Adaptation in the pharmaceutical industry, with particular reference to gastrointestinal drugs and diseases. Scand J Gastroenterol 1992, 27(Suppl. 193): 83-9.
2. Douthwaite, A.H., Lintott, S.A.M, Gastroscopic observation of the effect of aspirin and certain other substances on the stomach. Lancet 1938, 2: 1222-5.
3. Graham, D.Y., Smith, J.L., Holmes, G.I., Davies, R.O. Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa. Clin Pharmacol Ther 1985, 38: 65-70.
4. Carson, J.L., Strom, B.L., Soper, K.A., West, S.L., Morse, L. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med 1987, 147: 1054-9.
5. Wallace, J.L., McKnight, G.W. Characterization of a simple animal model for nonsteroidal anti-inflammatory drug induced antral ulcer. Can J Physiol Pharmacol 1993, 71: 447-52.
6. Hoftiezer, J.W., Silvoso, G.R., Burks, M., Ivey, K.J. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man. Lancet 1980, 2: 609-12.
7. Lanza, F.L., Nelson, R.S., Rack, M.F. A controlled endoscopic study comparing the toxic effects of sulindac, naproxen, aspirin and placebo on the gastric mucosa of healthy volunteers. J Clin Pharmacol 1984, 24: 89-95.
8. Kelly, J.P., Kaufman, D.W., Jurgelon, J.M., Sheehan, J., Koff, R.S., Shapiro, S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996, 348: 1413-6.
9. Wallace, J.L., Chin, B.C. NSAID-gastroenteropathy: Current therapy and diagnosis. Drugs Today 1997, 33: 115-22.
10. Bloom, B.S. Direct medical costs of disease and gastrointestinal side effects during treatment of arthritis. Am J Med 1988, 84(Suppl. 2A): 20-4.
11. Flower, R.J., Vane, J.R. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamide-phenol). Nature 1972, 120: 410-2.
12. Whittle, B.J.R., Higgs, G.A., Eakins, K.E., Moncada, S., Vane, J.R. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 1980, 284: 271-3.
13. Xie, W., Chipman, J.G., Robertson, D.L., Erikson, R.L., Simmons, D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991, 88: 2692-6.
14. Vane, J.R., Mitchell, J.A., Appleton, I. et al. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci USA 1994, 91: 2046-50.
15. Kargman, S., Charleson, S., Cartwright, M. et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tract. Gastroenterology 1996, 111: 445-54.
16. Mitchell, J.A., Akarasereenont, P., Thiemermann, C., Flower, R.J., Vane, J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993, 90: 11693-7.
17. Meade, E.A., Smith, W.L., DeWitt, D.L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993, 268: 6610-4.
18. Xie, W., Robertson, D.L., Simmons, D.L. Mitogen-inducible prostaglandin G/H synthase: A new target for nonsteroidal antiinflammatory drugs. Drug Dev Res 1992, 25: 249-65.
19. Glaser, K., Sung, M-L., O$Neill, K. et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995, 281: 107-11.
20. Willkens, R.F. An overview of the long-term safety experience of nabumetone. Drugs 1990, 40(Suppl. 5): 34-7.
21. Zvaifler, N. A review of the antiarthritic efficacy and safety of etodolac. Clin Rheumatol 1989, 8: 43-53.
22. Chan, C.C., Boyce, S., Brideau, C. et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal antiinflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995, 274: 1531-7.
23. Masferrer, J.L., Zweifel, B.S., Manning, P.T. et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994, 91: 3228-32.
24. Reuter, B.K., Asfaha, S., Buret, A., Sharkey, K.A., Wallace, J.L. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996, 98: 2076-85.
25. Mizuno, H., Sakamoto, C., Matsuda, K. et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997, 112: 387-97.
26. Slater, D.M., Berger, L.C., Newton, R., Moore, G.E., Bennett, P.R. Expression of cyclooxygenase types 1 and 2 in human fetal membranes at term. Am J Obstet Gynecol 1995, 172: 77-82.
27. Onoe, Y., Miyaura, C., Kaminakayashiki, T. et al. IL-13 and IL-14 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 1996, 156: 758-64.
28. Kubes, P., Wallace, J.L. Nitric oxide as a mediator of gastrointestinal injury - Say it ain't so. Med Inflamm 1995, 4: 397-405.
29. Whittle, B.J.R. Neuronal and endothelium-derived mediators in the modulation of the gastric microcirculation: Integrity in the balance. Br J Pharmacol 1993, 110: 3-17.
30. MacNaughton, W.K., Cirino, G., Wallace, J.L. Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci 1989, 45: 1869-76.
31. Kitagawa, H., Takeda, F., Kohei, H. Effect of endothelium-derived relaxing factor on the gastric lesion induced by HCI in rats. J Pharmacol Exp Ther 1990, 253: 1133-7.
32. Wallace, J.L. Mechanisms of NSAID-induced gastrointestinal damage - Potential for development of Gl-safe NSAIDs. Can J Physiol Pharmacol 1994, 71: 98-102.
33. Wallace, J.L., Reuter, B., Cicala, C., McKnight, W., Grisham, M.B., Cirino, G. Novel nonsterodial anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994, 107: 173-9.
34. Wallace, J.L., Reuter, B., Cicala, C., McKnight, W., Grisham, M., Cirino, G. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol 1994, 257: 249-55.
35. Reuter, B.K., Cirino, G., Wallace, J.L. Markedly reduced intestinal toxicity of a diclofenac derivative. Life Sci 1994, 55: PL1-8.
36. Cuzzolin, L., Conforti, A., Adami, A. et al. Anti-inflammatory potency and gastrointestinal toxicity of a new compound, NO-naproxen. Pharmacol Res 1995, 31: 61-5.
37. Davies, N.M., Roseth, A.G., Appleyard, C.B. et al. NO-naproxen vs. naproxen: Ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther 1997, 11: 69-79.
38. Mitchell, J.A., Cirino, G., Akarasereenont, P., Wallace, J.L., Flower, R.J., Vane, J.R. Flurbinitroxybutylester: A novel anti-inflammatory drug devoid of ulcerogenic activity, inhibits cyclo-oxygenase-1 and cyclo-oxgenase-2. Can J Physiol Pharmacol 1994, 72: 270 (Abst).
39. Wallace, J.L., Pittman, Q.J., Cirino, G. Nitric oxide releasing NSAIDs: A novel class of Gl-sparing anti-inflammatory drugs. In: New Molecular Approaches to Anti-Inflammatory Therapy Proznansky, W. (Ed.). Birkauser Verlag: Basel 1995, 121-9.
40. Radomski, M.W., Palmer, R.M.J., Moncada, S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987, 92: 181-7.
41. Meade, T.W., Roderick, P.J., Brennan, P.J., Wilkes, H.C., Kelleher, C.C. Extracranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemost 1992, 68: 1-6.
42. Cryer, B., Luk, G., Feldman, M. Effects of very low doses of aspirin (ASA) on gastric, duodenal & rectal prostaglandins (PGs) & mucosal injury. Gastroenterology 1995, 108: A77.
43. Kurata, J.H., Abbey, D.E. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalization. J Clin Gastroenterol 1990, 12: 260-6.
44. Wallace, J.L., McKnight, W., Del Soldato, P., Baydoun, A.R., Cirino, G. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest 1995, 96: 2711-8.
45. Lichtenberger, L.M. The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol 1995, 57: 565-83.
46. Goddard, P.J., Hills, B.A., Lictenberger, L.M. Does aspirin damage canine gastric mucosa by reducing its hydrophobicity? Am J Physiol 1987, 252: G421-30.
47. Lichtenberger, L.M., Wang, Z.M., Romero, J.J. et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1995, 1: 154-8.
48. Lichtenberger, L.M., Wang, Z.M., Giraud, M.N., Romero, J.J., Barretto, J.C. Effect of naproxen on gastric mucosal hydrophobicity. Gastroenterology 1995, 108: A149.
49. Hutt, A.J., Caldwell, J. The importance of stereochemistry in the clinical pharmacokinetics of the 2-arylpropionic acid non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 1984, 94: 371-3.
50. Brune, K., Beck, W.S., Geisslinger, G., Menzel-Soglowek, S., Peskar, B.M., Peskar, B.A. Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition. Experientia 1991, 47: 257-61.
51. Carabaza, A., Cabre, F., Rotllan, E. et al. Stereo-selective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs. J Clin Pharmacol 1996, 36: 502-12.
52. Reuter, B.K., Davies, N.M., Wallace, J.L. Non-steroidal anti-inflammatory drug enteropathy in rats: Role of permeability, bacteria and enterohepatic circulation. Gastroenterology 1997, 112: 109-17.
53. Wright, M.R., Davies, N.M., Jamali, F. Rationale for the development of stereochemically pure enantiomers: Are the R enantiomers of chiral nonsteroidal anti-inflammatory drugs inactive? J Pharm Sci 1994, 83: 911-2.
54. Davies, N.M., Wright, M.R., Russell, A.S., Jamali, F. Effect of enantiomers of flurbiprofen, ibuprofen, and ketoprofen on intestinal permeability. J Pharm Sci 1996, 85: 1170-3.
55. 2 at a cytoprotective dose. Gastroenterology 1985. 88: 1948-53.
56. 2, and carbenoxolone. Gastroenterology 1981, 80: 770-5.
57. Brown, J.F., Keates, A.C., Hanson, P.J., Whittle, B.J.R. Nitric oxide generators and cGMP stimulate mucus secretion by rat gastric mucosal cells. Am J Physiol 1993, 265: G418-22.
58. Asako, H., Kubes, P., Wallace, J.L., Wolf, R.E., Granger, D.N. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology 1992, 103: 146-52.
59. Kubes, P., Suzuki, M., Granger, D.N. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991, 88: 4651-5.
60. Robert, A. Cytoprotection by prostaglandins. Gastroenterology 1979, 77: 761-7.
61. Whittle, B.J.R. The potentiation of taurocholate-induced rat gastric erosions following parenteral administration of cyclo-oxygenase inhibitors. Br J Pharmacol 1983, 80: 545-51.